Nowadays pharmaceutical industries and regulatory authorities suggest new approaches such as Quality by Design principles to reduce experiments of formulation studies, improve product quality, save cost and time. SeDeM Expert System is a predictive approach for the preformulation studies and it provides information about suitability of API for direct compression by evaluating 12 parameters. The system also allows selecting appropriate excipients by determining same parameters to improve compressibility of API. The objective of this study was to develop direct compressed memantine orally disintegrating tablets using SeDeM Expert System. Memantine was found to have poor flow and compressibility properties. Three different direct compressibility and super disintegrating agents (Ludiflash^®, Ludipress^® and Parteck^®) were used to improve compressibility of memantine and according to SeDeM diagrams, Parteck^® was selected for final formulation. Memantine direct compressed tablets showed proper friability, hardness and thickness. The disintegration time of the tables were found below 15 s which was suitable for ODTs. It was found that SeDeM Expert System was easy to use and application of this method provided to develop memantine direct compressed ODT formulation was successful.

Eyes are one of the main critical organs of the body that provide our brain with the most information about the surrounding environment. Disturbance in the activity of this informational organ, resulting from different ocular diseases, could affect the quality of life, so finding appropriate methods for treating ocular disease has attracted lots of attention. This is especially due to the ineffectiveness of the conventional therapeutic method to deliver drugs into the interior parts of the eye, and the also presence of barriers such as tear film, blood-ocular, and blood-retina barriers. Recently, some novel techniques, such as different types of contact lenses, micro and nanoneedles and in situ gels, have been introduced which can overcome the previously mentioned barriers. These novel techniques could enhance the bioavailability of therapeutic components inside the eyes, deliver them to the posterior side of the eyes, release them in a controlled manner, and reduce the side effects of previous methods (such as eye drops). Accordingly, this review paper aims to summarize some of the evidence on the effectiveness of these new techniques for treating ocular disease, their preclinical and clinical progression, current limitations, and future perspectives.

Although the oral route is a common drug administration route, it still causes some patient compliance problems. Gummies are chewable gels that are commonly manufactured as dietary supplement carriers and their pharmaceutical use is still limited. Dexketoprofen trometamol is an anti-inflammatory and antipyretic drug. In the present study, dexketoprofen containing gummies were manufactured using carrageenan (Gelcarin ® GP-379) as the gel-forming polymer. Potassium dihydrogen phosphate (KH2PO4) was used as the gelling agent in the research. The obtained gummies were characterized. For this purpose, gel viscosity measurements, morphological and physical characterizations, thermal analysis, and in vitro drug release studies were carried out. The viscosity of the gel mixtures was measured at 50°C, which was the pouring temperature of the gels into molds. The formulation containing the highest carrageenan and KH2PO4 had the highest viscosity. The physical characterization results showed that the gummy formulations could be prepared in a reproducible manner. The DSC thermograms showed that the melting peak of DXT was not observed in the gummy formulation. The in vitro dissolution test results of the gummies showed that decreasing the carrageenan and KH2PO4 concentration in gummy formulation accelerated the drug release. The obtained gummies exhibited an extended-release of up to 2 hours.